Student Research Committee, Larestan University of Medical Sciences, Larestan, Iran.
Department of Medical Biochemical Analysis, Cihan University-Erbil, Kurdistan Region, Iraq.
Life Sci. 2024 Sep 1;352:122910. doi: 10.1016/j.lfs.2024.122910. Epub 2024 Jul 11.
Nectin-4 (Nectin cell adhesion molecule 4), a type I transmembrane cell adhesion protein, was demonstrated to be overexpressed in a variety of tumors, making it an attractive antigen for targeted therapies such as antibody-drug conjugates (ADCs). Of great note, the US Food and Drug Administration (FDA)-approval of the first Nectin-4-directed ADC, enfortumab vedotin (EV), in urothelial cancer (UC) not only introduced Nectin-4 as a clinically validated and reliable target antigen but also confirmed the evolving role of Nectin-4-directed ADCs as novel and promising cancer therapeutics. In addition to EV, there have been or are currently being seven and eleven Nectin-4-directed ADCs, respectively, in various stages of clinical trials and preclinical development, offering a promising future for the treatment of Nectin-4-positive cancer patients. This study reviewed clinical- and preclinical-stage Nectin-4-directed ADCs.
黏附分子 4（Nectin cell adhesion molecule 4，Nectin-4）是一种 I 型跨膜细胞黏附蛋白，在多种肿瘤中过表达，使其成为抗体药物偶联物（antibody-drug conjugate，ADC）等靶向治疗的理想抗原。值得注意的是，美国食品药品监督管理局（Food and Drug Administration，FDA）批准首个 Nectin-4 靶向 ADC 药物 enfortumab vedotin（EV）用于治疗膀胱癌，不仅将 Nectin-4 确定为经过临床验证且可靠的靶抗原，也证实了 Nectin-4 靶向 ADC 作为新型有前途的癌症治疗药物的不断发展的作用。除了 EV，目前有或正在进行分别处于临床试验和临床前开发的不同阶段的 7 种和 11 种 Nectin-4 靶向 ADC，为治疗 Nectin-4 阳性癌症患者提供了广阔的前景。本研究综述了临床和临床前阶段的 Nectin-4 靶向 ADC。
